within Pharmacolibrary.Drugs.ATC.L;

model L01FE03
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.1333333333333336e-07,
    adminDuration  = 600,
    adminMass      = 800 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0052,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0036,
    k12             = 0.0102,
    k21             = 0.0102
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01FE03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Necitumumab is a recombinant human IgG1 monoclonal antibody that binds to and inhibits the epidermal growth factor receptor (EGFR). It is used for the treatment of metastatic squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy. Necitumumab was approved by the FDA in 2015 for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in adult patients with advanced solid tumors and squamous NSCLC; population PK analysis.</p><h4>References</h4><ol><li><p>Dienstmann, R, &amp; Tabernero, J (2010). Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer. <i>Current opinion in investigational drugs (London, England : 2000)</i> 11(12) 1434–1441. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21154125/\">https://pubmed.ncbi.nlm.nih.gov/21154125</a></p></li><li><p>Reichert, JM (2015). Antibodies to watch in 2015. <i>mAbs</i> 7(1) 1–8. DOI:<a href=\"https://doi.org/10.4161/19420862.2015.988944\">10.4161/19420862.2015.988944</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25484055/\">https://pubmed.ncbi.nlm.nih.gov/25484055</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01FE03;
